Malignant Bladder Neoplasm
NCI Definition: A primary or metastatic malignant neoplasm involving the bladder. 
Malignant bladder neoplasms most frequently harbor alterations in TP53, KDM6A, KMT2D, FGFR3, and ARID1A .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, FGFR3 Mutation, and KMT2D Mutation are the most common alterations in malignant bladder neoplasm .
There are 5 clinical trials for malignant bladder neoplasm, of which 3 are open and 2 are completed or closed. Of the trials that contain malignant bladder neoplasm as an inclusion criterion, 2 are phase 1 (2 open) and 3 are phase 2 (1 open).
Aldesleukin, cyclophosphamide, and fludarabine are the most common interventions in malignant bladder neoplasm clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.